Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT03961568
Other study ID # YKP3089C033
Secondary ID
Status Enrolling by invitation
Phase Phase 3
First received
Last updated
Start date August 13, 2019
Est. completion date November 2025

Study information

Verified date February 2024
Source SK Life Science, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

52 Week Open-Label Safety Study of Cenobamate for Subjects who Complete YKP3089C025 (core study)


Description:

52 Week Open-Label Safety Study of cenobamate adjunctive therapy for subjects who complete double-blind study YKP3089C025. Subjects will have a 12 week double-blind conversion phase where subjects who received placebo in the double-blind study will be converted to cenobamate. Subjects who received cenobamate in the double-blind study will continue to receive their daily dose of cenobamate. Subjects switching from placebo to cenobamate will be titrated starting at 12.5 mg and increase their dose over the course of 12 weeks as follows 12.5 mg for 2 weeks, 25 mg for two weeks, 50 mg for two weeks, 100 mg for two weeks, 150 mg for two weeks, and 200 mg for two weeks. All subjects will receive 200 mg for the last two weeks of the conversion phase to preserve the blind. After completing the double-blind conversion phase, subjects will have 40 weeks of open-label, flexibly dosed cenobamate. The dose range is 50 mg - 200 mg. Primary endpoints are all safety measures. Adolescents will follow the same every two week regimen and receive cenobamate as an oral suspension based on weight


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 145
Est. completion date November 2025
Est. primary completion date May 2025
Accepts healthy volunteers No
Gender All
Age group 12 Years and older
Eligibility Inclusion Criteria: - The subject must have successfully completed the Double-blind Treatment Period in the Core study. - Written informed consent signed by the subject or legal guardian, prior to entering the study, in accordance with the International Council for Harmonisation (ICH) Good Clinical Practice (GCP) guidelines. If the written informed consent is provided by the legal guardian because the subject is unable to do so, a written or verbal assent from the subject must also be obtained. As required by country-specific regulations, only the subject may sign the ICF in accordance with ICH guidelines. Exclusion Criteria: - Subject tests positive, via urine drug screen at Visit 14 of the Core study, for illicit drugs except for tetrahydrocannabinol and Cannabinoids. - Any significant changes to the subject's medical history that, in the opinion of the Principal Investigator, could affect the subject's safety or conduct of the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cenobamate
active drug

Locations

Country Name City State
Bulgaria Multiprofile Hospital for Active Treatment Puls AD Blagoevgrad
Bulgaria Acibadem City Clinic Multiprofile Hospital for Active Treatment Tokuda EAD Sofia
Bulgaria Diagnostic Consultative Center Neoclinic EAD Sofia
Bulgaria Diagnostic Consultative Center Equita EOOD Varna
Bulgaria Medical Center Medica Plus OOD Veliko Tarnovo
Bulgaria Multiprofile Hospital for Active Treatment Sv. Ivan Rilski Gorna Oryahovitsa EOOD Veliko Tarnovo
Czechia Cerebrovaskularni poradna Ostrava-Poruba
Czechia Fakultni nemocnice v Motole Praha 5
Czechia Forbeli s.r.o.-Neurologicka ambulance Praha 6
Czechia Neurologicka ambulance Zlín
Hungary Semmelweis Egyetem I. Sz. Gyermekgyogyaszati Klinika Budapest
Poland Górnoslaskie Centrum Medyczne im. prof. Leszka Gieca Slaskiego Uniwersytetu Medycznego w Katowicach Katowice Silesia
Poland Centrum Leczenia Padaczki i Migreny Kraków Malopolskie
Poland Clinical Research Center Spólka z Ograniczona Odpowiedzialnoscia Medic-R sp. k. Poznan Wielkopolskie
Poland Centrum Medyczne Pratia Warszawa Warszawa Mazowieckie
Slovakia MUDr. Beata Dupejova, neurologicka ambulancia, s.r.o. Banská Bystrica
Slovakia IN MEDIC s.r.o. Bardejov
Slovakia Konzilium, s.r.o. Dubnica Nad Váhom
Ukraine Municipal Institution "Dnipropetrovsk City Clinical Hospital No16" of Dnipropetrovsk Regional Council Dnepropetrovsk Dnipropetrovsk
Ukraine Communal Institution "Dnipropetrovsk Regional Clinical Hospital n.a. I.I. Mechnikov", Regional Center Dnipropetrovs'k
Ukraine Municipal Institution "Dnipropetrovsk Regional Clinical Hospital named after I. I. Mechnikov" Dnipropetrovs'k
Ukraine Regional Psyconeurology Hospital #3 Ivano-Frankivs'k
Ukraine Communal Non-Commercial Enterprise of Kharkiv Regional Council Kharkiv
Ukraine Municipal Institution of Lviv Regional Council Lviv
Ukraine Municipal Institution Odesa Regional Clinical Hospital, Department of Cerebro-Vascular Diseases Odesa Odessa
Ukraine Ternopil Regional Municipal Psychoneurological Hospital Ternopil'
Ukraine Regional Clinical Center of Neurosurgery and Neurology "Uzhhorod National University" Úzhgorod Zakarpattia
Ukraine Municipal Institution "Vinnytsia Regional Psychoneurological Hospital named after Acad. O.I. Yushch Vinnytsya
Ukraine Municipal Institution Zaporizhzhia Regional Clinical Hospital of Zaporizhzhia Regional Council Zaporozhye Zaporizhzhya
United States Mid-Atlantic Epilepsy and Sleep Center Bethesda Maryland
United States Consultants in Epilepsy and Neurology, PLLC Boise Idaho
United States Minneapolis Clinic of Neurology Golden Valley Minnesota
United States Northeast Regional Epilepsy Group Hackensack New Jersey
United States Hawaii Pacific Neuroscience Honolulu Hawaii
United States University of California, San Diego (UCSD) La Jolla California
United States The Neurology Research Group, LLC. Miami Florida
United States University of Pennsylvania Philadelphia Pennsylvania
United States Valley Medical Center Renton Washington
United States Maine Medical Center Scarborough Maine
United States MultiCare Rockwood Neurology Center Spokane Washington
United States University of South Florida Tampa Florida
United States Five Towns Neuroscience Research Woodmere New York

Sponsors (1)

Lead Sponsor Collaborator
SK Life Science, Inc.

Countries where clinical trial is conducted

United States,  Bulgaria,  Czechia,  Hungary,  Poland,  Slovakia,  Ukraine, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Adverse Events and SAEs Summary statistics for clinical laboratory test results and vital signs; and physical examination, neurologic examination and electrocardiogram (ECG) finding. 386 +/- 2 days